Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Research & Development (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Research & Development data on record, last reported at $18.0 million in Q4 2025.

  • For Q4 2025, Research & Development rose 6.89% year-over-year to $18.0 million; the TTM value through Dec 2025 reached $64.3 million, up 20.48%, while the annual FY2025 figure was $64.3 million, 20.48% up from the prior year.
  • Research & Development reached $18.0 million in Q4 2025 per TARS's latest filing, up from $16.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $18.0 million in Q4 2025 and bottomed at $400000.0 in Q4 2022.
  • Average Research & Development over 5 years is $11.7 million, with a median of $12.2 million recorded in 2024.
  • Peak YoY movement for Research & Development: crashed 95.02% in 2022, then soared 3226.25% in 2023.
  • A 5-year view of Research & Development shows it stood at $8.0 million in 2021, then plummeted by 95.02% to $400000.0 in 2022, then skyrocketed by 3226.25% to $13.3 million in 2023, then rose by 26.82% to $16.9 million in 2024, then rose by 6.89% to $18.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $18.0 million in Q4 2025, $16.3 million in Q3 2025, and $15.6 million in Q2 2025.